Marika Ciprotti
Scientist
Andrew Scott Lab Ludwig Center at Melbourne
Ludwig Institute for Cancer Research
Australia
Biography
In addition to participation in genitourinary and gastrointestinal cancer clinics, my principal responsibilities involve the management of patients involved in early phase clinical trials with oncological malignancy: protocol development, regulatory affairs, trial conduct in line with GCP, and all aspects of trial clinical and administrative management and reporting. My translational research interests involve: • Clinical trials evaluating targeted biologic agents, particularly early phase trials with targeted antibodies. • Development of investigator-initiated clinical trial concepts • Application of optical imaging and biomarkers to clinical trials
Research Interest
Genitourinary and gastrointestinal cancer, clinical trials
Publications
-
Kelly, Ronan Joseph, et al. "CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer." (2017): TPS212-TPS212.
-
Gan, Hui Kong, et al. "A phase I and biodistribution study of ABT-806i, an 111indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806." (2013): 2520-2520.
-
Ciprotti, Marika, et al. "Phase I imaging and pharmacodynamic trial of CS-1008 in patients with metastatic colorectal cancer." Journal of clinical oncology 33.24 (2015): 2609-2616.
